Characterising patients with COPD by baseline short-acting ß2-agonist (SABA) use: a post hoc analysis of the EMAX trial
E. Kerwin (Medford, OR, United States of America), I. Boucot (Brentford, Middlesex, United Kingdom), L. Bjermer (Lund, Sweden), F. Maltais (Québec, QC, Canada), P. Jones (Brentford, Middlesex, United Kingdom), L. Tombs (Stockley Park West, Uxbridge, Middlesex, United Kingdom), D. Lipson (Collegeville and Philadelphia, PA, United States of America), C. Compton (Brentford, Middlesex, United Kingdom), C. Vogelmeier (Marburg, Germany)
Source: Virtual Congress 2020 – Clinical studies of COPD: combination inhalers and much more
Disease area: Airway diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
E. Kerwin (Medford, OR, United States of America), I. Boucot (Brentford, Middlesex, United Kingdom), L. Bjermer (Lund, Sweden), F. Maltais (Québec, QC, Canada), P. Jones (Brentford, Middlesex, United Kingdom), L. Tombs (Stockley Park West, Uxbridge, Middlesex, United Kingdom), D. Lipson (Collegeville and Philadelphia, PA, United States of America), C. Compton (Brentford, Middlesex, United Kingdom), C. Vogelmeier (Marburg, Germany). Characterising patients with COPD by baseline short-acting ß2-agonist (SABA) use: a post hoc analysis of the EMAX trial. 982
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: